Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids

Rheumatology (Oxford). 2019 Jun 1;58(6):1106-1109. doi: 10.1093/rheumatology/key447.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Drug Therapy, Combination
  • Humans
  • Lymphohistiocytosis, Hemophagocytic / chemically induced
  • Lymphohistiocytosis, Hemophagocytic / drug therapy*
  • Male
  • Prostatic Neoplasms / drug therapy
  • Steroids / therapeutic use*
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Steroids
  • pembrolizumab
  • Tacrolimus